Back

AB Science targets 2027 resumption for AB8939 and masitinib trials

Verifying
  • AB Science revised its development plan after a sponsor GCP inspection.
  • Five inspectors from authorities in France, Denmark and Greece conducted the inspection September 21-25.
  • AB8939 and masitinib trial resumptions are targeted for early and late 2027, respectively.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.